Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 12 tags : Vaccine save search
Late in the Game, CureVac Lays Down COVID Vaccine for a Better Hand
Published: 2021-10-12 (Crawled : 15:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.72%
H: 0.1%
C: -0.06%
covid vaccine
Pfizer-BioNTech Lead Globally with COVID-19 Vaccine
Published: 2021-10-12 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
covid vaccine covid-19
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
Published: 2021-10-12 (Crawled : 14:15) - biospace.com/
MRNA | News S | $104.48 3.03% 2.94% 3.1M
|
Health Technology
|
| O: 2.6%
H: 0.93%
C: -0.61%
covid vaccine
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-10-12 (Crawled : 13:00) - inovio.com
INO | $10.005 3.36% 3.25% 330K
|
Health Technology
|
| O: 2.06%
H: 0.58%
C: -0.29%
covid vaccine ino-4800
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $27.07 4.2% 4.03% 310K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.28 -3.03% -3.13% 51K
|
Health Technology
|
| O: 1.46%
H: 3.77%
C: 2.88%
covid vaccine
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
CVAC | $2.525 3.48% 3.37% 600K
|
Health Technology
|
| O: -13.04%
H: 13.08%
C: 9.7%
covid vaccine technology covid-19
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.